Zydus gets USFDA nod for Arsenic Trioxide Injection
New Delhi: Zydus Cadila has received the final approval from the USFDA to market Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL) single-dose vial (US RLD – TRISENOX®). It will be manufactured at Alidac Pharmaceuticals Ltd., the company’s wholly-owned subsidiary located at SEZ, Ahmedabad.
Arsenic Trioxide is used to treat a type of leukaemia (acute promyelocytic leukemia-APL) when other types of treatment (e.g., chemotherapy) have not worked well or no longer work.
The group now has 228 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Read Also: Zydus Cadila gets USFDA nod for Anti-Fungal Ointment
Arsenic Trioxide is used to treat a type of leukaemia (acute promyelocytic leukemia-APL) when other types of treatment (e.g., chemotherapy) have not worked well or no longer work.
The group now has 228 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Read Also: Zydus Cadila gets USFDA nod for Anti-Fungal Ointment
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd